Table 2 A comparison of clinical characteristics the DR-TB cases reviewed by the national DR-TB consilium with those not reviewed
Clinical characteristic | Review status | |||
|---|---|---|---|---|
Not reviewed n = 933 | 95% CI | Reviewed n = 189 | 95% CI | |
Body mass index, kg/m2 n = 473 | ||||
< 18.5 | 195 (55.9) | 50.6, 61.0 | 81 (65.3) | 56.5, 73.2 |
18.5–24.9 | 142 (40.7) | 35.6, 45.9 | 39 (31.5) | 23.8, 40.2 |
25.0–29.9 | 12 (3.4) | 2.0, 6.0 | 4 (3.2) | 1.2, 8.4 |
History of TB treatment | ||||
Yes | 556 (59.6) | 56.4, 62.7 | 107 (56.6) | 49.4, 63.5 |
No | 377 (40.4) | 37.3, 43.6 | 82 (43.4) | 36.5, 50.6 |
HIV Status | ||||
Positive | 564 (60.5) | 57.3, 63.5 | 102 (54) | 46.8, 61.0 |
Negative | 369 (39.5) | 36.5, 42.7 | 87 (46) | 39.0, 53.2 |
Cotrimoxazole use, n = 603 | ||||
Yes | 491 (97) | 95.1, 98.2 | 96 (99) | 92.9, 99.9 |
No | 15 (3) | 1.8, 4.9 | 1 (1) | 0.1, 7.1 |
ART use, n = 655 | ||||
Yes | 521 (94) | 91.7, 95.7 | 101 (100) | - |
No | 33 (6) | 4.3, 8.3 | 0 (0) | - |
History of ART default, n = 491 | ||||
Yes | 60 (14.7) | 11.6, 18.5 | 26 (31) | 21.9, 41.8 |
No | 347 (85.3) | 81.5, 88.4 | 58 (69) | 58.2, 78.1 |
Diabetes, n = 151 | ||||
Yes | 36 (33) | 24.8, 42.5 | 12 (28.6) | 16.7, 44.4 |
No | 73 (67) | 57.5, 75.2 | 30 (71.4) | 55.6, 83.3 |
Hypertension, n = 479 | ||||
Yes | 19 (4.6) | 2.9, 7.0 | 5 (8.1) | 3.3, 18.2 |
No | 398 (95.4) | 93.0, 97.1 | 57 (91.9) | 81.8, 96.7 |
Systolic blood pressure, n = 479 | ||||
< 90 | 32 (7.7) | 5.5, 10.7 | 10 (16.1) | 8.8, 28.7 |
90–140 | 375 (89.9) | 86.6, 92.5 | 48 (77.4) | 65.1, 86.3 |
> 140 | 10 (2.4) | 1.3, 4.4 | 4 (6.5) | 2.4, 16.2 |
Diastolic blood pressure, n = 479 | ||||
< 60 | 41 (9.8) | 7.3, 13.1 | 10 (16.1) | 8.8, 27.7 |
60–90 | 362 (86.8) | 83.2, 89.7 | 51 (82.3) | 70.5, 90.0 |
> 90 | 14 (3.4) | 2.0, 5.6 | 1 (1.6) | 0.2, 11.0 |
Cancer | ||||
No | 919 (98.5) | 97.5, 99.1 | 186 (98.4) | 95.2, 99.5 |
Yes | 14 (1.5) | 0.9, 2.5 | 3 (1.6) | 0.5, 4.8 |
Elevated creatinine†, n = 934 | ||||
Yes | 231 (29.4) | 26.3, 32.6 | 48 (32.7) | 25.5, 40.7 |
No | 556 (70.6) | 67.4, 73.7 | 99 (67.3) | 59.3, 74.5 |
Hepatic injury§, n = 928 | ||||
Yes | 639 (82.8) | 79.9, 85.3 | 141 (90.4) | 84.6, 94.1 |
No | 133 (17.2) | 14.7, 20.1 | 15 (9.6) | 5.9, 15.4 |
Hearing impairment, n = 803 | ||||
Normal Hearing | 351 (54.5) | 50.6, 58.3 | 93 (58.5) | 50.6, 65.9 |
Low Frequency | 113 (17.5) | 14.8, 20.7 | 24 (15.1) | 10.3, 21.6 |
High Frequency | 180 (28) | 24.6, 31.6 | 42 (26.4) | 20.1, 33.9 |
Distribution of hearing loss, n = 348 | ||||
Bilateral hearing loss | 233 (80.9) | 75.9, 85.1 | 55 (91.7) | 81.2, 96.6 |
Unilateral hearing loss | 55 (19.1) | 14.9, 24.1 | 5 (8.3) | 3.4, 18.8 |
Grade of hearing loss, n = 314 | ||||
Mild | 145 (55.3) | 49.2, 61.3 | 20 (38.5) | 26.1, 52.6 |
Moderate | 65 (24.8) | 19.9, 30.4 | 18 (34.6) | 22.8, 48.7 |
Severe | 34 (13) | 9.4, 17.6 | 9 (17.3) | 9.1, 30.4 |
Profound | 18 (6.9) | 4.4, 10.7 | 5 (9.6) | 4.0, 21.5 |
Psychiatric symptoms | ||||
Yes | 49 (5.3) | 4.0, 6.9 | 20 (10.6) | 6.9, 15.9 |
No | 884 (94.7) | 93.1, 96.0 | 169 (89.4) | 84.1, 93.1 |
Resistance to SLDs | ||||
Yes | 4 (0.4) | 0.1, 1.1 | 9 (4.8) | 2.5, 8.9 |
No | 929 (99.6) | 98.9, 99.8 | 180 (95.2) | 91.1, 97.5 |
Previous exposure to SLDS | ||||
Yes | 17 (1.8) | 1.1, 2.9 | 13 (6.9) | 4.0, 11.5 |
No | 916 (98.2) | 97.1, 98.9 | 176 (93.1) | 88.5, 96.0 |